Boston Scientific’s PolarCath peripheral dilatation system has demonstrated positive results from the COBRA clinical trial, which investigated post-dilation of nitinol stents using CryoPlasty therapy.

CryoPlasty therapy uses nitrous oxide to fill an angioplasty balloon within a blocked artery to treat atherosclerotic lesions in the peripheral arteries.

The COBRA trial randomised 76 patients with 90 superficial femoral artery lesions to CryoPlasty therapy or conventional balloon angioplasty for post-dilation of nitinol stents.

The prospective, randomised, multicentre trial showed a 47% relative reduction in binary restenosis rates for patients treated with PolarCath system compared to stenting with conventional balloon angioplasty.

In the study, the primary endpoint was the rate of binary in-segment restenosis determined by duplex ultrasonography, while the secondary endpoint included change in the ankle-brachial index from baseline in 12 months.

Principal investigator of the study Subhash Banerjee said CryoPlasty therapy can reduce binary restenosis at 12 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.